Clinical Trial Update: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating chemotherapy with or without atezolizumab in stage III colon cancer with mismatch repair deficiency; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Lynch Syndrome

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colon Adenocarcinoma, DNA Repair Disorder | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-14